LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Global Point-of-Care Molecular Diagnostics Market to Be Driven by Rising Instances of Infectious Diseases

By LabMedica International staff writers
Posted on 27 Dec 2021
Print article
Illustration
Illustration

The global market for point-of-care (PoC) molecular diagnostics is predicted to record a solid growth over the next couple of years due to a rise in instances of infectious diseases and increasing public awareness about pre-disease detection. Additionally, growing research and development due to increased funding by both government and private entities, leading to new and better products being rolled out, will also have a positive impact on the market.

These are the latest findings of TMR Research (San Francisco, CA, USA), a provider of market research and consulting services.

PoC testing in diagnostics which mainly entail tests that are portable and generate rapid results is fast gaining traction. Molecular tests that study the genetic material of an infectious disease are gaining maximum traction since they are swift, portable, hassle-free to conduct, and cost less. Hospitals and other healthcare centers are eagerly adopting them because of the convenience they offer. PoC diagnostics finds usage in the domains of oncology, infectious diseases, and hematology and endocrinology. Out of these, infectious diseases are driving most of the demand in the market mainly on account of rising cases of Zika and other viruses causing deadly maladies. Quick unraveling of the causative agents of infectious diseases is the key to treating them successfully. Going forward, progress in DNA sequencing and analysis is expected to further speed up accurate detection of the causative agents. This kind of technological progress is expected to provide a further impetus to the market for PoC diagnostics.

Currently, the market for PoC molecular diagnostics is being dominated by a few top manufacturers. These vendors are competing against one another based on pricing and product quality. They are frequently upgrading their products to more effective ones. However, a key factor posing a challenge to market growth is the duration of time needed for developing molecular diagnostic products. This is because the development process consists of numerous stages involving prototype designing, research, testing, and pre- and post-marketing activities. Besides, complicated regulatory processes are also restraining market growth.

Geographically, the uptake of PoC molecular diagnostics is the highest in North America owing to the increasing occurrence of both cancer and infectious diseases in the region. Another factor that makes North America a market leader is the presence of several key players in the region which has resulted in the introduction of various PoC molecular diagnostics products. However, with new companies entering the fray, competition in the worldwide PoC molecular diagnostics market is set to heat up in the near future.

Related Links:
TMR Research 

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more